Prognostic Significance of the Loss of Heterozygosity of

KRAS LOH NSCLC copy number aberration prognostic marker

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 10 02 2022
accepted: 31 03 2022
entrez: 16 5 2022
pubmed: 17 5 2022
medline: 17 5 2022
Statut: epublish

Résumé

Lung cancer is a common disease with a poor prognosis. Genomic alterations involving the

Identifiants

pubmed: 35574381
doi: 10.3389/fonc.2022.873532
pmc: PMC9098994
doi:

Types de publication

Journal Article

Langues

eng

Pagination

873532

Informations de copyright

Copyright © 2022 Khadse, Haakensen, Silwal-Pandit, Hamfjord, Micke, Botling, Brustugun, Lingjærde, Helland and Kure.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Diagn Mol Pathol. 2011 Sep;20(3):158-65
pubmed: 21817902
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
Eur J Cancer. 2012 Jun;48(9):1299-311
pubmed: 22464348
Radiology. 2017 Jan;282(1):251-258
pubmed: 27440441
PLoS One. 2013 Oct 24;8(10):e78614
pubmed: 24205279
Nat Genet. 2013 Oct;45(10):1127-33
pubmed: 24071851
BMC Cancer. 2021 Oct 9;21(1):1089
pubmed: 34625038
Eur Respir J. 2012 Jul;40(1):177-84
pubmed: 22267755
Mol Oncol. 2016 Feb;10(2):330-43
pubmed: 26601720
Int J Cancer. 2013 May 1;132(9):2020-31
pubmed: 23023297
J Clin Oncol. 2007 Nov 20;25(33):5240-7
pubmed: 18024870
Br J Cancer. 2010 Mar 16;102(6):1024-31
pubmed: 20197771
Lung Cancer. 2019 Apr;130:50-58
pubmed: 30885352
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Commun. 2020 Feb 5;11(1):715
pubmed: 32024838
Elife. 2015 Jun 05;4:e06907
pubmed: 26047463
Lung Cancer. 2016 Sep;99:102-10
pubmed: 27565922
PLoS One. 2017 Nov 7;12(11):e0187246
pubmed: 29112949
J Clin Oncol. 2013 Jun 10;31(17):2173-81
pubmed: 23630215
PLoS One. 2012;7(2):e31906
pubmed: 22363766
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Cell Adh Migr. 2010 Jan-Mar;4(1):100-6
pubmed: 20139701
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Genes Dev. 2005 Mar 15;19(6):643-64
pubmed: 15769940
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15823-15829
pubmed: 31332011
Cancer Sci. 2004 Mar;95(3):197-204
pubmed: 15016317
Cancer Lett. 2017 Jan 1;384:86-93
pubmed: 27725226
Mol Cancer. 2006 Jun 19;5:25
pubmed: 16784539
Clin Cancer Res. 2008 Sep 15;14(18):5731-4
pubmed: 18794081
PLoS One. 2012;7(5):e36530
pubmed: 22590557
Nature. 2007 Dec 6;450(7171):893-8
pubmed: 17982442
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):990-5
pubmed: 26747605
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Semin Cell Dev Biol. 2016 Oct;58:60-9
pubmed: 27422332
Oncogene. 2013 Aug 22;32(34):4028-33
pubmed: 22945650
Lung Cancer. 2018 Aug;122:138-145
pubmed: 30032822
Respir Med. 2005 Mar;99(3):308-12
pubmed: 15733506
J Thorac Oncol. 2011 Nov;6(11):1833-40
pubmed: 22011649

Auteurs

Anand Khadse (A)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Faculty of Technology, Natural Sciences and Maritime Sciences, Department of Natural Sciences and Environmental Health, University of South-Eastern Norway, Bø i Telemark, Norway.

Vilde D Haakensen (VD)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Department of Oncology, Oslo University Hospital, Oslo, Norway.

Laxmi Silwal-Pandit (L)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Julian Hamfjord (J)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Department of Oncology, Oslo University Hospital, Oslo, Norway.

Patrick Micke (P)

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Johan Botling (J)

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Odd Terje Brustugun (OT)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.

Ole Christian Lingjærde (OC)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.

Åslaug Helland (Å)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Department of Oncology, Oslo University Hospital, Oslo, Norway.
Department of Clinical Medicine, University of Oslo, Oslo, Norway.

Elin H Kure (EH)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Faculty of Technology, Natural Sciences and Maritime Sciences, Department of Natural Sciences and Environmental Health, University of South-Eastern Norway, Bø i Telemark, Norway.

Classifications MeSH